Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial (IPF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02874989

Recruitment Status : Completed

First Posted : August 22, 2016

Last Update Posted : May 12, 2020

Sponsor:

Collaborators:

Mayo Clinic

The University of Texas Health Science Center at San Antonio

Information provided by (Responsible Party):

Wake Forest University Health Sciences

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	June 3, 2019
Actual Study Completion Date :	June 3, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, Prata L, Masternak MM, Kritchevsky SB, Musi N, Kirkland JL. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019 Feb;40:554-563. doi: 10.1016/j.ebiom.2018.12.052. Epub 2019 Jan 5.

To Top